{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T16:06:08Z","timestamp":1791302768383,"version":"4.1.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2012,8,1]],"date-time":"2012-08-01T00:00:00Z","timestamp":1343779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2012,8]]},"DOI":"10.1016\/j.semarthrit.2012.01.003","type":"journal-article","created":{"date-parts":[[2012,3,29]],"date-time":"2012-03-29T11:55:54Z","timestamp":1333022154000},"page":"42-55","source":"Crossref","is-referenced-by-count":108,"title":["Treatment of Systemic Sclerosis Complications: What to Use When First-Line Treatment Fails\u2014A Consensus of Systemic Sclerosis Experts"],"prefix":"10.1016","volume":"42","author":[{"given":"Kyle M.","family":"Walker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet","family":"Pope","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.semarthrit.2012.01.003_bib1","first-page":"1867","article-title":"Increased prevalence of scleroderma in southwestern Ontario: A cluster analysis","volume":"29","author":"Thompson","year":"2002","journal-title":"J Rheumatol"},{"issue":"3","key":"10.1016\/j.semarthrit.2012.01.003_bib2","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1097\/MD.0b013e3181dde28d","article-title":"Systemic sclerosis: Establishing diagnostic criteria","volume":"89","author":"Hudson","year":"2010","journal-title":"Medicine (Baltimore)"},{"issue":"6","key":"10.1016\/j.semarthrit.2012.01.003_bib3","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1097\/BOR.0b013e3283310d57","article-title":"Disease-modifying treatment in systemic sclerosis: Current status","volume":"21","author":"Quillinan","year":"2009","journal-title":"Curr Opin Rheumatol"},{"issue":"7","key":"10.1016\/j.semarthrit.2012.01.003_bib4","first-page":"1573","article-title":"Criteria for the classification of early systemic sclerosis","volume":"28","author":"Leroy","year":"2001","journal-title":"J Rheumatol"},{"issue":"5","key":"10.1016\/j.semarthrit.2012.01.003_bib5","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1177\/0885066610371181","article-title":"Care of patients with scleroderma in the intensive care setting","volume":"25","author":"Farber","year":"2010","journal-title":"J Intensive Care Med"},{"issue":"6","key":"10.1016\/j.semarthrit.2012.01.003_bib6","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1002\/1529-0131(199906)42:6<1194::AID-ANR16>3.0.CO;2-7","article-title":"High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis: Analysis of a two-year, double-blind, randomized, controlled clinical trial","volume":"42","author":"Clements","year":"1999","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.semarthrit.2012.01.003_bib7","doi-asserted-by":"crossref","first-page":"419","DOI":"10.2165\/00003495-200161030-00008","article-title":"Drug treatment of scleroderma","volume":"61","author":"Leighton","year":"2001","journal-title":"Drugs"},{"issue":"6","key":"10.1016\/j.semarthrit.2012.01.003_bib8","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1002\/1529-0131(200106)44:6<1351::AID-ART227>3.0.CO;2-I","article-title":"A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma","volume":"44","author":"Pope","year":"2001","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.semarthrit.2012.01.003_bib9","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/j.1756-185X.2009.01410.x","article-title":"The manifestations of vasculopathy in systemic sclerosis and its evidence-based therapy","volume":"12","author":"Strange","year":"2009","journal-title":"Int J Rheum Dis"},{"issue":"3","key":"10.1016\/j.semarthrit.2012.01.003_bib10","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.berh.2009.12.002","article-title":"Evidence-based management of rapidly progressing systemic sclerosis","volume":"24","author":"Khanna","year":"2010","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"5","key":"10.1016\/j.semarthrit.2012.01.003_bib11","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/ard.2008.095299","article-title":"European league against rheumatism (EULAR) scleroderma trial and research group (EUSTAR) recommendations for the treatment of systemic sclerosis: Methods of elaboration and results of systematic literature research","volume":"68","author":"Avouac","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.semarthrit.2012.01.003_bib12","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1136\/ard.2008.096677","article-title":"EULAR recommendations for the treatment of systemic sclerosis: A report from the EULAR scleroderma trials and research group (EUSTAR)","volume":"68","author":"Kowal-Bielecka","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 10","key":"10.1016\/j.semarthrit.2012.01.003_bib13","first-page":"1203","article-title":"Combination antibiotics for Chlamydia-induced arthritis: Breakthrough to a cure?","volume":"62","author":"Harding","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.semarthrit.2012.01.003_bib14","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1002\/art.21714","article-title":"Scleroderma treatment differs between experts and general rheumatologists","volume":"55","author":"Pope","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.semarthrit.2012.01.003_bib15","first-page":"84","article-title":"The modified Rodnan skin score is an accurate reflection of skin biopsy thickness in systemic sclerosis","volume":"25","author":"Furst","year":"1998","journal-title":"J Rheumatol"},{"issue":"19","key":"10.1016\/j.semarthrit.2012.01.003_bib16","doi-asserted-by":"crossref","first-page":"2980","DOI":"10.1161\/CIRCULATIONAHA.104.523324","article-title":"Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy","volume":"112","author":"Fries","year":"2005","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.semarthrit.2012.01.003_bib17","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1093\/rheumatology\/keq291","article-title":"Modified-release sildenafil reduces Raynaud's phenomenon attack frequency in limited cutaneous systemic sclerosis","volume":"63","author":"Herrick","year":"2011","journal-title":"Arthritis Rheum"},{"issue":"12","key":"10.1016\/j.semarthrit.2012.01.003_bib18","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.3899\/jrheum.101262","article-title":"Efficacy of tadalafil in secondary Raynaud's phenomenon resistant to vasodilator therapy: A double-blind randomized cross-over trial","volume":"49","author":"Shenoy","year":"2010","journal-title":"Rheumatol Oxf Engl"},{"issue":"7","key":"10.1016\/j.semarthrit.2012.01.003_bib19","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.3899\/jrheum.101262","article-title":"Expert agreement on EULAR\/EUSTAR recommendations for the management of systemic sclerosis","volume":"38","author":"Walker","year":"2011","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2012.01.003_bib20","doi-asserted-by":"crossref","DOI":"10.1155\/2010\/347402","article-title":"An international, web-based prospective cohort to determine whether the use of ACE inhibitors prior to the onset of scleroderma renal crisis is associated with worse outcomes\u2014Methodology and preliminary results","volume":"2010","author":"Hudson","year":"2010","journal-title":"Int J Rheumatol"},{"issue":"1","key":"10.1016\/j.semarthrit.2012.01.003_bib21","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1097\/BOR.0b013e3283108df7","article-title":"Mortality and risk factors of scleroderma renal crisis: A French retrospective study of 50 patients","volume":"67","author":"Teixeira","year":"2008","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.semarthrit.2012.01.003_bib22","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1002\/1529-0131(199809)41:9<1613::AID-ART11>3.0.CO;2-O","article-title":"Diagnosis, management and prevention of scleroderma renal disease","volume":"20","author":"Penn","year":"2008","journal-title":"Curr Opin Rheumatol"},{"issue":"9","key":"10.1016\/j.semarthrit.2012.01.003_bib23","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1136\/bmj.d5931","article-title":"Case-control study of corticosteroids and other drugs that either precipitate or protect from the development of scleroderma renal crisis","volume":"41","author":"Steen","year":"1998","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2012.01.003_bib24","doi-asserted-by":"crossref","first-page":"d5931","DOI":"10.1016\/j.reprotox.2011.02.008","article-title":"Maternal exposure to angiotensin converting enzyme inhibitors in the first trimester and risk of malformations in offspring: a retrospective cohort study","volume":"343","author":"Li","year":"2011","journal-title":"BMJ"},{"issue":"4","key":"10.1016\/j.semarthrit.2012.01.003_bib25","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/S0146-0005(97)80055-9","article-title":"Pregnancy outcome after in utero exposure to angiotensin converting enzyme inhibitors or angiotensin receptor blockers","volume":"31","author":"Diav-Citrin","year":"2011","journal-title":"Reprod Toxicol"},{"issue":"2","key":"10.1016\/j.semarthrit.2012.01.003_bib26","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1183\/09059180.00007810","article-title":"Angiotensin converting enzyme inhibitors in pregnancy","volume":"21","author":"Mastrobattista","year":"1997","journal-title":"Semin Perinatol"},{"key":"10.1016\/j.semarthrit.2012.01.003_bib27","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1056\/NEJMoa055120","article-title":"Early intervention in pulmonary arterial hypertension associated with systemic sclerosis: An essential component of disease management","volume":"19","author":"Hachulla","year":"2010","journal-title":"Eur Respir Rev"},{"issue":"25","key":"10.1016\/j.semarthrit.2012.01.003_bib28","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1056\/NEJMoa055120","article-title":"Cyclophosphamide versus placebo in scleroderma lung disease","volume":"354","author":"Tashkin","year":"2006","journal-title":"N Engl J Med"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017212000170?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017212000170?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,26]],"date-time":"2019-06-26T07:00:19Z","timestamp":1561532419000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017212000170"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,8]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,8]]}},"alternative-id":["S0049017212000170"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2012.01.003","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2012,8]]}}}